Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Immunicum

DB:1YG
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1YG
DB
SEK646M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immunicum AB (publ) develops therapeutic cancer vaccines. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Immunicum has significant price volatility in the past 3 months.
1YG Share Price and Events
7 Day Returns
1.3%
DB:1YG
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-14.6%
DB:1YG
-7.4%
DE Biotechs
-14.2%
DE Market
1YG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immunicum (1YG) 1.3% -4.7% -33.6% -14.6% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 1YG underperformed the Biotechs industry which returned -7.4% over the past year.
  • 1YG matched the Germany Market (-14.2%) over the past year.
Price Volatility
1YG
Industry
5yr Volatility vs Market

1YG Value

 Is Immunicum undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immunicum. This is due to cash flow or dividend data being unavailable. The share price is €0.647.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immunicum's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immunicum's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1YG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-1.46
OM:IMMU Share Price ** OM (2020-04-08) in SEK SEK7
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immunicum.

DB:1YG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:IMMU Share Price ÷ EPS (both in SEK)

= 7 ÷ -1.46

-4.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunicum is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immunicum is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immunicum's expected growth come at a high price?
Raw Data
DB:1YG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
36.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immunicum, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immunicum's assets?
Raw Data
DB:1YG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK2.96
OM:IMMU Share Price * OM (2020-04-08) in SEK SEK7
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:1YG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:IMMU Share Price ÷ Book Value per Share (both in SEK)

= 7 ÷ 2.96

2.37x

* Primary Listing of Immunicum.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunicum is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immunicum's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immunicum has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1YG Future Performance

 How is Immunicum expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immunicum expected to grow at an attractive rate?
  • Unable to compare Immunicum's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Immunicum's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Immunicum's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1YG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1YG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 36.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1YG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1YG Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 243 1
2022-12-31 0 -77 -77 1
2021-12-31 99 85 -19 2
2020-12-31 0 -135 -135 2
2020-04-08
DB:1YG Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 -146 -134
2019-09-30 -114 -118
2019-06-30 -102 -112
2019-03-31 -89 -98
2018-12-31 -105 -98
2018-09-30 -88 -90
2018-06-30 -89 -89
2018-03-31 -94 -88
2017-12-31 -46 -80
2017-09-30 -76 -86
2017-06-30 -75 -77
2017-03-31 -68 -72

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immunicum is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Immunicum is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1YG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Immunicum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1YG Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 -0.83 -0.83 -0.83 1.00
2021-12-31 -0.21 0.92 -1.34 2.00
2020-12-31 -1.46 -1.46 -1.46 1.00
2020-04-08
DB:1YG Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -1.46
2019-09-30 -1.44
2019-06-30 -1.56
2019-03-31 -1.54
2018-12-31 -1.90
2018-09-30 -2.01
2018-06-30 -2.32
2018-03-31 -2.81
2017-12-31 -3.09
2017-09-30 -3.37
2017-06-30 -2.92
2017-03-31 -2.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immunicum will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Immunicum's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immunicum has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1YG Past Performance

  How has Immunicum performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immunicum's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immunicum does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immunicum's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immunicum's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immunicum's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immunicum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1YG Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -134.02 28.50 103.14
2019-09-30 -118.22 26.45 91.37
2019-06-30 -112.10 26.65 84.87
2019-03-31 -98.23 25.77 71.87
2018-12-31 -97.86 25.61 70.93
2018-09-30 -90.47 24.59 65.51
2018-06-30 -88.61 23.32 65.14
2018-03-31 -88.47 22.18 66.03
2017-12-31 -80.34 22.81 57.81
2017-09-30 -86.32 41.27 44.56
2017-06-30 -76.65 48.35 27.73
2017-03-31 -72.45 57.94 14.02
2016-12-31 -61.42 60.86
2016-09-30 -48.09 47.47
2016-06-30 -43.92 43.34
2016-03-31 -36.71 36.74
2015-12-31 -37.71 37.88
2015-09-30 -37.26 37.87
2015-06-30 -35.61 36.41
2015-03-31 -33.39 33.96
2014-12-31 -27.79 28.32
2014-09-30 -20.56 21.62
2014-06-30 -16.18 17.14
2014-03-31 -13.32 14.13
2013-12-31 -10.29 11.11
2013-09-30 -7.59 7.72
2013-06-30 -6.89 6.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immunicum has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immunicum has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immunicum improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immunicum's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immunicum has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1YG Health

 How is Immunicum's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immunicum's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immunicum is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immunicum's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immunicum's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 357.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immunicum Company Filings, last reported 3 months ago.

DB:1YG Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 272.78 0.85 296.81
2019-09-30 314.79 0.85 334.09
2019-06-30 344.44 0.85 363.41
2019-03-31 376.90 0.85 393.36
2018-12-31 406.04 0.85 443.80
2018-09-30 117.91 0.85 133.27
2018-06-30 141.43 0.85 149.97
2018-03-31 160.79 0.85 168.06
2017-12-31 189.56 0.85 128.88
2017-09-30 40.87 0.85 53.11
2017-06-30 62.53 0.85 70.73
2017-03-31 81.75 0.85 93.85
2016-12-31 102.39 0.85 112.43
2016-09-30 127.19 0.85 129.03
2016-06-30 139.18 0.85 129.44
2016-03-31 38.84 0.85 42.94
2015-12-31 45.33 0.85 53.11
2015-09-30 56.81 0.85 61.44
2015-06-30 64.63 0.85 68.17
2015-03-31 72.43 0.85 75.77
2014-12-31 83.05 0.85 87.11
2014-09-30 94.07 0.85 97.77
2014-06-30 100.24 0.85 107.84
2014-03-31 14.01 0.85 16.96
2013-12-31 19.02 0.85 20.20
2013-09-30 24.60 0.85 25.61
2013-06-30 24.60 0.85 25.61
  • Immunicum's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1% vs 0.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immunicum has sufficient cash runway for 2 years based on current free cash flow.
  • Unable to confirm if Immunicum has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Immunicum's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immunicum has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1YG Dividends

 What is Immunicum's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immunicum dividends. Estimated to be 0% next year.
If you bought €2,000 of Immunicum shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immunicum's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immunicum's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1YG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1YG Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immunicum has not reported any payouts.
  • Unable to verify if Immunicum's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immunicum's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immunicum has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Immunicum's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Immunicum's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immunicum afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immunicum has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1YG Management

 What is the CEO of Immunicum's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alex Karlsson-Parra
COMPENSATION SEK0
AGE 69
TENURE AS CEO 0.3 years
CEO Bio

Mr. Alex Karlsson-Parra, M.D., Ph.D. is the Founder of Immunicum AB and has been its Chief Scientific Officer since 2008. He serves as Interim Chief Executive Officer at Immunicum AB (publ) since December 13, 2019. Mr. Karlsson-Parra has extensive experience from work within the field of transplantation immunology. He served as the Chairman of the Swedish Expert Committee in Clinical Immunology.

CEO Compensation
  • Insufficient data for Alex to compare compensation growth.
  • Alex's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Immunicum management team in years:

2.3
Average Tenure
63.5
Average Age
  • The tenure for the Immunicum management team is about average.
Management Team

Per-Olof Gunnesson

TITLE
Advisor Contracts
COMPENSATION
SEK162K
AGE
74
TENURE
4.2 yrs

Alex Karlsson-Parra

TITLE
Founder
AGE
69
TENURE
0.3 yrs

Michaela Gertz

TITLE
Chief Financial Officer
TENURE
2.2 yrs

Sijme Zeilemaker

TITLE
COO & Senior Director of Business Development
TENURE
0.3 yrs

Margareth Jorvid

TITLE
Head of Regulatory affairs & QA
AGE
58
TENURE
4.3 yrs

Sharon Longhurst

TITLE
Head of CMC
AGE
50
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the Immunicum board of directors in years:

3.4
Average Tenure
59
Average Age
  • The tenure for the Immunicum board of directors is about average.
Board of Directors

Michael S. Oredsson

TITLE
Chairman
AGE
59
TENURE
2 yrs

Kerstin Strinnholm

TITLE
Independent Director
COMPENSATION
SEK31K
AGE
59
TENURE
3.4 yrs

Gunnar Magnus Severus Persson

TITLE
Independent Director
COMPENSATION
SEK69K
AGE
59
TENURE
4.3 yrs

Charlotte Edenius

TITLE
Independent Director
COMPENSATION
SEK38K
AGE
61
TENURE
3.4 yrs

Steven Glazer

TITLE
Independent Director
COMPENSATION
SEK44K
AGE
71
TENURE
3.4 yrs

Pawel Kalinski

TITLE
Member of Scientific Advisory Board
TENURE
1.6 yrs

Inge Svane

TITLE
Member of Scientific Advisory Board
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Dec 19 Buy Margareth Jorvid Individual 02. Dec 19 02. Dec 19 10,000 €0.89 €8,906
30. Aug 19 Buy Carlos de Sousa Individual 29. Aug 19 29. Aug 19 10,000 €0.80 €7,966
X
Management checks
We assess Immunicum's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immunicum has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1YG News

Simply Wall St News

1YG Company Info

Description

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase I/II clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company’s products also comprise IMM-2 platform, which is in preclinical trials is transfected with an adenoviral vector to deliver tumor antigens directly to the cells; and IMM-3 platform, which is in a preclinical phase study optimized CAR-T expansion protocol for improved anti-cancer activity. Immunicum AB (publ) has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study. The company is headquartered in Stockholm, Sweden.

Details
Name: Immunicum AB (publ)
1YG
Exchange: DB
Founded:
SEK59,169,446
92,257,531
Website: http://immunicum.se
Address: Immunicum AB (publ)
Östermalmstorg 5,
Stockholm,
Stockholm County, 114 42,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM IMMU Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 22. Apr 2013
DB 1YG Ordinary Shares Deutsche Boerse AG DE EUR 22. Apr 2013
BATS-CHIXE IMMUS Ordinary Shares BATS 'Chi-X Europe' GB SEK 22. Apr 2013
Number of employees
Current staff
Staff numbers
11
Immunicum employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:30
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/04/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.